ANZCTR search results

Women undergoing D&C surgery often experience pain afterwards between 2 and 7 on a scale of 1-10. This pain is intially due to surgical trauma but may continue because of resulting inflammation. If the ongoing cycle of inflammation is reduced pain may be less. Pregabalin is a treatment for seizure disorders. It also has pain relieving and calming properties. It can reduce local tissue inflammation and the release of pain mediators. Therefore pregabalin given preoperatively may reduce postoperative pain.

Phase 3 This sub-study is assessing the effects of the drug anastrozole on bone mineral density and other indicators on bone strength, when this drug is used to prevent breast cancer in postmenopausal women. This is an ANZ02P2/International Breast cancer Intervention Study: IBIS II Bone Sub-Protocol. Who is it for? You can join this trial if: You are joining the ANZ02P2 International Breast cancer Intervention Study: IBIS II (Prevention).You must not have not previously have had bilateral hip fractures or bilateral hip prostheses. You must not have a metabolic bone disease. You can not have regularly taken any medication affecting bone metabolism within the past 12 months unless you have been diagnosed as osteoporotic and are currently taking oral bisphosphonate (a bone strengthening drug). Trial details Participants will be divided into three groups based on the results of their baseline bone mineral density scans. Group 1 will comprise of participants with normal bone density. It will be recommended that these participants take calcium and vitamin D supplements. Group 2 will comprise of participants with osteopaenia (or reduced bone mineral density). These participants will be divided into two groups. One group will take the drug risedronate orally once a week for 5 years while the other group takes an inactive compound. It will be recommended that these participants also take calcium and vitamin D supplements. Group 3 consists of participants diagnosed with osteoporosis (low bone mineral density). These participants will take risedronate orally once a week for 5 years. All women in this sub-study (Groups 1, 2 and 3) will be monitored with bone mineral density scans. Risedronate is a type of drug called a bisphosphonate which acts to increase bone mass and strength.

Trial completed and published 2009 Flisberg P, Paech MJ, Shah T, Ledowski T, Kurowski I, Parsons R. Induction dose of propofgol in patients using cannabis. Euro J Anaesthesiol 2009;26:192-5